Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.04.2024 | Case report

Trastuzumab

Left ventricular ejection fraction decline

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Nag S, et al. A Prospective, Single arm, Multicentre, Post-marketing Study (Phase IV) to evaluate safety and immunogenicity of Dr. Reddy's Trastuzumab (DRL_TZ) in Patients with HER2-Positive Advanced Breast Cancer. European Journal of Cancer 200 (Suppl.): Mar 2024. Available from: URL: https://dx.doi.org/10.1016/j.ejca.2024.113709 [abstract] Nag S, et al. A Prospective, Single arm, Multicentre, Post-marketing Study (Phase IV) to evaluate safety and immunogenicity of Dr. Reddy's Trastuzumab (DRL_TZ) in Patients with HER2-Positive Advanced Breast Cancer. European Journal of Cancer 200 (Suppl.): Mar 2024. Available from: URL: https://​dx.​doi.​org/​10.​1016/​j.​ejca.​2024.​113709 [abstract]
Metadaten
Titel
Trastuzumab
Left ventricular ejection fraction decline
Publikationsdatum
01.04.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-56612-8

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Amiodarone

Case report

Mitotane

Case report

Multiple drugs